C
Cyrus V. Hedvat
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 81
Citations - 11368
Cyrus V. Hedvat is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Leukemia & Haematopoiesis. The author has an hindex of 39, co-authored 76 publications receiving 10186 citations. Previous affiliations of Cyrus V. Hedvat include New York University & Kettering University.
Papers
More filters
Journal ArticleDOI
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens,Marco L. Davila,Isabelle Riviere,Jae H. Park,Xiuyan Wang,Lindsay G. Cowell,Shirley Bartido,Jolanta Stefanski,Clare Taylor,Malgorzata Olszewska,Oriana Borquez-Ojeda,Jinrong Qu,Teresa Wasielewska,Qing He,Yvette Bernal,Ivelise Rijo,Cyrus V. Hedvat,Rachel Kobos,Kevin J. Curran,Peter G. Steinherz,Joseph G. Jurcic,Todd L. Rosenblat,Peter Maslak,Mark G. Frattini,Michel Sadelain +24 more
TL;DR: The results demonstrate the marked antitumor efficacy of 19-28z CAR-modified T cells in patients with relapsed/refractory B-ALL and the reliability of this therapy to induce profound molecular remissions, forming a highly effective bridge to potentially curative therapy with subsequent allo-HSCT.
Journal ArticleDOI
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward,Jay P. Patel,David R. Wise,Omar Abdel-Wahab,Bryson D. Bennett,Hilary A. Coller,Justin R. Cross,Valeria Fantin,Cyrus V. Hedvat,Alexander E. Perl,Joshua D. Rabinowitz,Martin Carroll,Shinsan M. Su,Kim A. Sharp,Ross L. Levine,Craig B. Thompson +15 more
TL;DR: It is reported that tumor 2HG is elevated in a high percentage of patients with cytogenetically normal acute myeloid leukemia (AML), and AML patients with IDH mutations display a significantly reduced number of other well characterized AML-associated mutations and/or associated chromosomal abnormalities, potentially implicating IDH mutation in a distinct mechanism of AML pathogenesis.
Journal ArticleDOI
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton,Alex Fichtenholtz,Geoff Otto,Kai Wang,Sean R. Downing,Jie He,Michael Schnall-Levin,Jared White,Eric M. Sanford,Peter An,James Sun,Frank Juhn,Kristina W. Brennan,Kiel Iwanik,Ashley Maillet,Jamie Buell,Emily White,Mandy Zhao,Sohail Balasubramanian,Selmira Terzic,Tina Richards,Vera Banning,Lazaro Garcia,Kristen Mahoney,Zac Zwirko,Amy Donahue,Himisha Beltran,Himisha Beltran,Juan Miguel Mosquera,Juan Miguel Mosquera,Mark A. Rubin,Mark A. Rubin,Snjezana Dogan,Cyrus V. Hedvat,Michael F. Berger,Lajos Pusztai,Matthias Lechner,Chris Boshoff,Mirna Jarosz,Christine Vietz,Alexander N. Parker,Vincent A. Miller,Jeffrey S. Ross,Jeffrey S. Ross,John Curran,Maureen T. Cronin,Philip J. Stephens,Doron Lipson,Roman Yelensky +48 more
TL;DR: A test based on massively parallel DNA sequencing to characterize base substitutions, short insertions and deletions (indels), copy number alterations and selected fusions across 287 cancer-related genes from routine formalin-fixed and paraffin-embedded (FFPE) clinical specimens is described.
Journal ArticleDOI
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Omar Abdel-Wahab,Ann Mullally,Cyrus V. Hedvat,Guillermo Garcia-Manero,Jay P. Patel,Martha Wadleigh,Sébastien Malinge,Jin Juan Yao,Outi Kilpivaara,Rukhmi Bhat,Kety Huberman,Sabrena Thomas,Igor Dolgalev,Adriana Heguy,Elisabeth Paietta,Michelle M. Le Beau,Miloslav Beran,Martin S. Tallman,Benjamin L. Ebert,Benjamin L. Ebert,Hagop M. Kantarjian,Richard Stone,D. Gary Gilliland,D. Gary Gilliland,D. Gary Gilliland,John D. Crispino,Ross L. Levine +26 more
TL;DR: In this paper, the mutational status of TET1, TET2, and TET3 in myeloproliferative neoplasms (MPNs), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) was evaluated.
Journal Article
p63 Expression Profiles in Human Normal and Tumor Tissues
Charles J. Di Como,Marshall J. Urist,Irina Babayan,Marija Drobnjak,Cyrus V. Hedvat,Julie Teruya-Feldstein,Kamal S. Pohar,Axel Hoos,Carlos Cordon-Cardo +8 more
TL;DR: The data support a role for p63 in squamous and transitional cell carcinomas, as well as certain lymphomas and thymomas, and in adenocarcinomas, including those of breast and prostate.